Oxidative stress and respiratory system: Pharmacological and clinical reappraisal of N-acetylcysteine

Pierachille Santus, Angelo Corsico, Paolo Solidoro, Fulvio Braido, Fabiano Di Marco, Nicola Scichilone

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a "multilevel cycle" responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of this review was to provide a comprehensive overview of the role of oxidative stress in the pathogenesis of respiratory diseases, particularly COPD, and to examine the available clinical and experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The proposed concept of "multilevel cycle" helps understand the relationship between respiratory diseases and oxidative stress, thus clarifying the rationale for using NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC may reduce the rate of COPD exacerbations and improve small airways function. The most plausible explanation for the beneficial effects observed in patients with COPD treated with NAC lies in the mucolytic and antioxidant effects of this drug. Modulation of bronchial inflammation by NAC may further account for these favorable clinical results.

Original languageEnglish
Pages (from-to)705-717
Number of pages13
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume11
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Acetylcysteine
Respiratory System
Chronic Obstructive Pulmonary Disease
Oxidative Stress
Pharmacology
Antioxidants
Expectorants
Oxidants
Smoke
Tobacco Products
Pharmaceutical Preparations
Glutathione
Disease Progression
Reactive Oxygen Species
Leukocytes
Homeostasis
Gases
Clinical Trials
Inflammation
Wounds and Injuries

Keywords

  • Antioxidant
  • Copd exacerbation
  • Lung function
  • Small airways

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Oxidative stress and respiratory system : Pharmacological and clinical reappraisal of N-acetylcysteine. / Santus, Pierachille; Corsico, Angelo; Solidoro, Paolo; Braido, Fulvio; Di Marco, Fabiano; Scichilone, Nicola.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 11, No. 6, 01.12.2014, p. 705-717.

Research output: Contribution to journalArticle

Santus, Pierachille ; Corsico, Angelo ; Solidoro, Paolo ; Braido, Fulvio ; Di Marco, Fabiano ; Scichilone, Nicola. / Oxidative stress and respiratory system : Pharmacological and clinical reappraisal of N-acetylcysteine. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2014 ; Vol. 11, No. 6. pp. 705-717.
@article{27547a978d0d4194afaf0d4f04ce561e,
title = "Oxidative stress and respiratory system: Pharmacological and clinical reappraisal of N-acetylcysteine",
abstract = "The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a {"}multilevel cycle{"} responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of this review was to provide a comprehensive overview of the role of oxidative stress in the pathogenesis of respiratory diseases, particularly COPD, and to examine the available clinical and experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The proposed concept of {"}multilevel cycle{"} helps understand the relationship between respiratory diseases and oxidative stress, thus clarifying the rationale for using NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC may reduce the rate of COPD exacerbations and improve small airways function. The most plausible explanation for the beneficial effects observed in patients with COPD treated with NAC lies in the mucolytic and antioxidant effects of this drug. Modulation of bronchial inflammation by NAC may further account for these favorable clinical results.",
keywords = "Antioxidant, Copd exacerbation, Lung function, Small airways",
author = "Pierachille Santus and Angelo Corsico and Paolo Solidoro and Fulvio Braido and {Di Marco}, Fabiano and Nicola Scichilone",
year = "2014",
month = "12",
day = "1",
doi = "10.3109/15412555.2014.898040",
language = "English",
volume = "11",
pages = "705--717",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Oxidative stress and respiratory system

T2 - Pharmacological and clinical reappraisal of N-acetylcysteine

AU - Santus, Pierachille

AU - Corsico, Angelo

AU - Solidoro, Paolo

AU - Braido, Fulvio

AU - Di Marco, Fabiano

AU - Scichilone, Nicola

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a "multilevel cycle" responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of this review was to provide a comprehensive overview of the role of oxidative stress in the pathogenesis of respiratory diseases, particularly COPD, and to examine the available clinical and experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The proposed concept of "multilevel cycle" helps understand the relationship between respiratory diseases and oxidative stress, thus clarifying the rationale for using NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC may reduce the rate of COPD exacerbations and improve small airways function. The most plausible explanation for the beneficial effects observed in patients with COPD treated with NAC lies in the mucolytic and antioxidant effects of this drug. Modulation of bronchial inflammation by NAC may further account for these favorable clinical results.

AB - The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a "multilevel cycle" responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of this review was to provide a comprehensive overview of the role of oxidative stress in the pathogenesis of respiratory diseases, particularly COPD, and to examine the available clinical and experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The proposed concept of "multilevel cycle" helps understand the relationship between respiratory diseases and oxidative stress, thus clarifying the rationale for using NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC may reduce the rate of COPD exacerbations and improve small airways function. The most plausible explanation for the beneficial effects observed in patients with COPD treated with NAC lies in the mucolytic and antioxidant effects of this drug. Modulation of bronchial inflammation by NAC may further account for these favorable clinical results.

KW - Antioxidant

KW - Copd exacerbation

KW - Lung function

KW - Small airways

UR - http://www.scopus.com/inward/record.url?scp=84910648710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910648710&partnerID=8YFLogxK

U2 - 10.3109/15412555.2014.898040

DO - 10.3109/15412555.2014.898040

M3 - Article

C2 - 24787454

AN - SCOPUS:84910648710

VL - 11

SP - 705

EP - 717

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 6

ER -